Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-06-14 | Brian M. Culley. Mr. Culley joined BioTime as Chief Executive Officer in September 2018. ... Brian M. Culley does not qualify as “independent” under Section 803(A) of the NYSE American Company Guide because he is our Chief Executive Officer. Mr. Culley, our only director who is also an employee of ours, receives compensation in his capacity as an employee but is not compensated for serving as a director or attending meetings of our Board. |
| 2020-08-07 | Brian M. Culley joined Lineage as Chief Executive Officer in September 2018. ... Brian M. Culley does not qualify as “independent” under Section 803(A) of the NYSE American Company Guide because he is our Chief Executive Officer. |
| 2021-08-03 | Brian M. Culley. Mr. Culley joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021. ... Mr. Culley brings to our Board significant knowledge of the biotechnology industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies. |
| 2022-04-29 | Brian M. Culley. Mr. Culley joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021. ... Mr. Culley brings to our Board significant knowledge of the biotechnology industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies. ... The following table shows the annual cash fees currently paid to our directors for their service on our Board and on committees of our Board. ... Director other than Chair $40,000. ... Our Board has determined that Mr. Culley does not qualify as an “independent” director under Section 803(A) of the NYSE American Company Guide because he is our Chief Executive Officer. |
| 2023-07-27 | Brian M. Culley. Mr. Culley joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. ... Mr. Culley brings to our Board significant knowledge of the biotechnology industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies. ... Our Board has an Audit Committee, a Nominating and Corporate Governance Committee, and a Compensation Committee. ... The table below sets forth the composition of the committees of our Board as of July 20, 2023: ... Brian M. Culley Member Compensation Committee, Member Financial Strategy Committee. ... Mr. Culley does not qualify as an “independent” director under Section 803(A) of the NYSE American Company Guide because he is our Chief Executive Officer. |
| 2024-04-29 | Brian M. Culley. Mr. Culley joined Lineage as Chief Executive Officer in September 2018 ... Our Board has determined that Mr. Culley does not qualify as an “independent” director ... The table below sets forth the composition of the committees of our Board as of April 25, 2024: ... Brian M. Culley: Audit Committee Member, Financial Strategy Committee Member ... 2023 Non-Employee Director Compensation Table: Brian M. Culley is an employee and does not receive non-employee director compensation. |
| 2024-12-09 | By Order of the Board of Directors, /s/ Brian M. Culley Brian M. Culley Chief Executive Officer and Director |
Data sourced from SEC filings. Last updated: 2025-12-06